Shire PLC (NASDAQ:SHPG) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,535,236 shares, an increase of 32.5% from the August 15th total of 1,158,579 shares. Based on an average daily volume of 1,336,807 shares, the short-interest ratio is currently 1.1 days.

Several equities research analysts recently weighed in on SHPG shares. HSBC Holdings plc cut Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday, May 19th. Sanford C. Bernstein cut Shire PLC from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $209.22 to $161.09 in a research note on Thursday, May 25th. Cowen and Company reaffirmed an “outperform” rating and issued a $325.00 price target on shares of Shire PLC in a research note on Wednesday, May 31st. Liberum Capital cut Shire PLC from a “buy” rating to a “hold” rating in a research note on Thursday, June 1st. Finally, ValuEngine cut Shire PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, ten have given a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $220.08.

Shire PLC (NASDAQ:SHPG) opened at 158.46 on Friday. The company has a market capitalization of $47.20 billion, a P/E ratio of 70.90 and a beta of 1.61. The stock’s 50 day moving average price is $153.42 and its 200-day moving average price is $168.82. Shire PLC has a one year low of $139.36 and a one year high of $209.22.

Shire PLC (NASDAQ:SHPG) last announced its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Equities analysts forecast that Shire PLC will post $14.93 EPS for the current year.

The firm also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be paid a dividend of $0.1527 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is 41.07%.

A number of hedge funds have recently made changes to their positions in the stock. Maverick Capital Ltd. grew its stake in Shire PLC by 19.9% during the 2nd quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after buying an additional 322,610 shares during the last quarter. Glenview Capital Management LLC grew its stake in Shire PLC by 69.7% during the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after buying an additional 707,500 shares during the last quarter. Vanguard Group Inc. grew its stake in Shire PLC by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Shire PLC by 14.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock worth $249,577,000 after buying an additional 194,059 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Shire PLC by 4,217.7% during the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares during the last quarter. Hedge funds and other institutional investors own 19.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/09/16/shire-plc-shpg-sees-significant-increase-in-short-interest.html.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.